Genomic analysis of globally diverse Mycobacterium tuberculosis strains provides insights into emergence and spread of multidrug resistance

Multidrug-resistant tuberculosis (MDR-TB), caused by drug-resistant strains of Mycobacterium tuberculosis, is an increasingly serious problem worldwide. Here we examined a data set of whole-genome sequences from 5,310 M. tuberculosis isolates from five continents. Despite the great diversity of these isolates with respect to geographical point of isolation, genetic background and drug resistance, the patterns for the emergence of drug resistance were conserved globally. We have identified harbinger mutations that often precede multidrug resistance. In particular, the katG mutation encoding p.Ser315Thr, which confers resistance to isoniazid, overwhelmingly arose before mutations that conferred rifampicin resistance across all of the lineages, geographical regions and time periods. Therefore, molecular diagnostics that include markers for rifampicin resistance alone will be insufficient to identify pre-MDR strains. Incorporating knowledge of polymorphisms that occur before the emergence of multidrug resistance, particularly katG p.Ser315Thr, into molecular diagnostics should enable targeted treatment of patients with pre-MDR-TB to prevent further development of MDR-TB.

Thomas Abeel | James E. Galagan | Andrei Gabrielian | Alex Rosenthal | Ted Cohen | Parissa Farnia | David Alland | Bruce W. Birren | Po-Ren Hsueh | Alex Salazar | Laura E. Via | Abigail L. Manson | Ashlee M. Earl | Sujatha Narayanan | Christopher A. Desjardins | Valeriu Crudu | Gail H. Cassell | B. Birren | S. Dorman | J. Galagan | W. Bishai | S. Swaminathan | A. Gabrielian | D. Alland | M. L. van der Walt | Sang-Nae Cho | A. Rosenthal | T. Cohen | A. Earl | T. Abeel | J. Ellner | A. Velayati | S. Chapman | C. Desjardins | P. Hsueh | L. Via | C. Barry | K. Winglee | M. Joloba | A. Pym | S. Narayanan | D. Armstrong | W. Ssengooba | A. Skrahina | V. Crudu | P. Juréen | S. Hoffner | William R. Bishai | Soumya Swaminathan | Daniela Homorodean | M. Maiga | A. Manson | G. Cassell | Kathryn Winglee | James Gomez | Clifton E. Barry | Jong Seok Lee | Sven Hoffner | Sang-Nae Cho | Keira A. Cohen | Derek T. Armstrong | Jeannette Brand | Sinéad B. Chapman | Andreea M. Jodals | Moses Joloba | Pontus Jureen | Lesibana Malinga | Mamoudou Maiga | Dale Nordenberg | Ecaterina Noroc | Elena Romancenco | Willy Ssengooba | A. A. Velayati | Aksana Zalutskaya | Susan E. Dorman | Jerrold Ellner | Alexander S. Pym | Alena Skrahina | Martie Van der Walt | P. Farnia | A. Zalutskaya | K. Cohen | Alex N. Salazar | E. Romancenco | M. Walt | J. Brand | L. Malinga | D. Homorodean | E. Noroc | James Gomez | Dale Nordenberg | Jeannette Pontus Lesibana Dale A A Gail H Parissa Daniela Ma Brand Jureen Malinga Nordenberg Velayat | P. Juréen | Elena Romancenco

[1]  A. Nunn,et al.  Global tuberculosis drug development pipeline: the need and the reality , 2010, The Lancet.

[2]  Jukka Corander,et al.  Evolution and transmission of drug resistant tuberculosis in a Russian population , 2014, Nature Genetics.

[3]  C. Daborn,et al.  The epidemiology of Mycobacterium bovis infections in animals and man: a review. , 1995, Tubercle and lung disease : the official journal of the International Union against Tuberculosis and Lung Disease.

[4]  Dick van Soolingen,et al.  Epidemiology of Isoniazid Resistance Mutations and Their Effect on Tuberculosis Treatment Outcomes , 2013, Antimicrobial Agents and Chemotherapy.

[5]  R. Kao,et al.  Whole Genome Sequencing Reveals Local Transmission Patterns of Mycobacterium bovis in Sympatric Cattle and Badger Populations , 2012, PLoS pathogens.

[6]  A. Benedetti,et al.  Treatment of isoniazid-resistant tuberculosis with first-line drugs: a systematic review and meta-analysis. , 2017, The Lancet. Infectious diseases.

[7]  A. Catanzaro,et al.  Genetic Mutations Associated with Isoniazid Resistance in Mycobacterium tuberculosis: A Systematic Review , 2015, PloS one.

[8]  M. Suchard,et al.  Bayesian Phylogenetics with BEAUti and the BEAST 1.7 , 2012, Molecular biology and evolution.

[9]  K. Dooley,et al.  Fluoroquinolone resistance in patients with newly diagnosed tuberculosis. , 2003, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

[10]  P. Small,et al.  Impact of Bacterial Genetics on the Transmission of Isoniazid-Resistant Mycobacterium tuberculosis , 2006, PLoS pathogens.

[11]  Nalin Rastogi,et al.  Evolutionary history and global spread of the Mycobacterium tuberculosis Beijing lineage , 2015, Nature Genetics.

[12]  W. Fawzi,et al.  Multi Drug and Other Forms of Drug Resistant Tuberculosis Are Uncommon among Treatment Naïve Tuberculosis Patients in Tanzania , 2015, PloS one.

[13]  W. Jacobs,et al.  inhA, a gene encoding a target for isoniazid and ethionamide in Mycobacterium tuberculosis. , 1994, Science.

[14]  Raymund B. Dantes,et al.  Clinical characteristics and treatment outcomes of patients with isoniazid-monoresistant tuberculosis. , 2009, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

[15]  D. Hughes,et al.  Genetic characterization of compensatory evolution in strains carrying rpoB Ser531Leu, the rifampicin resistance mutation most frequently found in clinical isolates. , 2013, The Journal of antimicrobial chemotherapy.

[16]  A. Aseffa,et al.  Mycobacterium tuberculosis Lineage 7 Strains Are Associated with Prolonged Patient Delay in Seeking Treatment for Pulmonary Tuberculosis in Amhara Region, Ethiopia , 2015, Journal of Clinical Microbiology.

[17]  G. Alangaden,et al.  Mechanism of Resistance to Amikacin and Kanamycin in Mycobacterium tuberculosis , 1998, Antimicrobial Agents and Chemotherapy.

[18]  A. Zaha,et al.  Characterization of pncA Mutations in Pyrazinamide-Resistant Mycobacterium tuberculosis in Brazil , 2005, Antimicrobial Agents and Chemotherapy.

[19]  Ying Zhang,et al.  pncA Mutations as a Major Mechanism of Pyrazinamide Resistance in Mycobacterium tuberculosis: Spread of a Monoresistant Strain in Quebec, Canada , 2000, Antimicrobial Agents and Chemotherapy.

[20]  P. Butcher,et al.  High-dose rifapentine with moxifloxacin for pulmonary tuberculosis. , 2014, The New England journal of medicine.

[21]  Peter Lackner,et al.  MAESTRO - multi agent stability prediction upon point mutations , 2015, BMC Bioinformatics.

[22]  S. Cole,et al.  Missense mutations in the catalase‐peroxidase gene, katG, are associated with isoniazid resistance in Mycobacterium tuberculosis , 1995, Molecular microbiology.

[23]  Adam P. Arkin,et al.  FastTree: Computing Large Minimum Evolution Trees with Profiles instead of a Distance Matrix , 2009, Molecular biology and evolution.

[24]  J. T. Crawford,et al.  ethA, inhA, and katG Loci of Ethionamide-Resistant Clinical Mycobacterium tuberculosis Isolates , 2003, Antimicrobial Agents and Chemotherapy.

[25]  H. Soini,et al.  katG mutations in isoniazid-resistant Mycobacterium tuberculosis isolates recovered from Finnish patients , 1996, Antimicrobial agents and chemotherapy.

[26]  L. Via,et al.  Mutations in gidB Confer Low-Level Streptomycin Resistance in Mycobacterium tuberculosis , 2011, Antimicrobial Agents and Chemotherapy.

[27]  J. T. Crawford,et al.  Characterization of Spontaneous, In Vitro-Selected, Rifampin-Resistant Mutants of Mycobacterium tuberculosisStrain H37Rv , 2000, Antimicrobial Agents and Chemotherapy.

[28]  J. Sacchettini,et al.  Modification of the NADH of the isoniazid target (InhA) from Mycobacterium tuberculosis. , 1998, Science.

[29]  J. Chien,et al.  Treatment outcome of patients with isoniazid mono-resistant tuberculosis. , 2015, Clinical microbiology and infection : the official publication of the European Society of Clinical Microbiology and Infectious Diseases.

[30]  S. Cole,et al.  Streptomycin resistance in mycobacteria , 1994, Antimicrobial Agents and Chemotherapy.

[31]  Julian Parkhill,et al.  Inferring patient to patient transmission of Mycobacterium tuberculosis from whole genome sequencing data , 2013, BMC Infectious Diseases.

[32]  M. Donald Cave,et al.  Population Genetics Study of Isoniazid Resistance Mutations and Evolution of Multidrug-Resistant Mycobacterium tuberculosis , 2006, Antimicrobial Agents and Chemotherapy.

[33]  W. Bishai,et al.  Whole Genome Sequencing of Mycobacterium africanum Strains from Mali Provides Insights into the Mechanisms of Geographic Restriction , 2016, PLoS neglected tropical diseases.

[34]  I. Bastian,et al.  Tuberculosis in Australia: bacteriologically confirmed cases and drug resistance, 2010. A report of the Australian Mycobacterium Reference Laboratory Network. , 2013, Communicable diseases intelligence quarterly report.

[35]  M. Makino,et al.  Characterization of the rpsL and rrs genes of streptomycin‐resistant clinical isolates of Mycobacterium tuberculosis in Japan , 1997, Journal of applied microbiology.

[36]  A. Velayati,et al.  High prevelance of rifampin-monoresistant tuberculosis: a retrospective analysis among Iranian pulmonary tuberculosis patients. , 2014, The American journal of tropical medicine and hygiene.

[37]  I. Sugawara,et al.  The molecular epidemiology of ethambutol-resistant Mycobacterium tuberculosis in Henan Province, China. , 2005, Japanese journal of infectious diseases (Print).

[38]  Sonya S. Shin,et al.  The dilemma of MDR-TB in the global era. , 1998, The international journal of tuberculosis and lung disease : the official journal of the International Union against Tuberculosis and Lung Disease.

[39]  Victor DeGruttola,et al.  Bayesian Estimation of Mixture Models with Prespecified Elements to Compare Drug Resistance in Treatment-Naïve and Experienced Tuberculosis Cases , 2013, PLoS Comput. Biol..

[40]  H. Marrakchi,et al.  InhA, a target of the antituberculous drug isoniazid, is involved in a mycobacterial fatty acid elongation system, FAS-II. , 2000, Microbiology.

[41]  D. van Soolingen,et al.  Possible underlying mechanisms for successful emergence of the Mycobacterium tuberculosis Beijing genotype strains. , 2010, The Lancet. Infectious diseases.

[42]  A. Diacon,et al.  Early Bactericidal Activity of High-Dose Rifampin in Patients with Pulmonary Tuberculosis Evidenced by Positive Sputum Smears , 2007, Antimicrobial Agents and Chemotherapy.

[43]  Yuqing Li,et al.  Characterization of rifampin-resistant isolates of Mycobacterium tuberculosis from Sichuan in China. , 2013, Tuberculosis.

[44]  Thomas Abeel,et al.  Genomic and functional analyses of Mycobacterium tuberculosis strains implicate ald in D-cycloserine resistance , 2016, Nature Genetics.

[45]  Razvan Sultana,et al.  Genomic Analysis Identifies Targets of Convergent Positive Selection in Drug Resistant Mycobacterium tuberculosis , 2013, Nature Genetics.

[46]  W. Jacobs,et al.  Genetic Manipulation of Mycobacterium tuberculosis , 2007, Current protocols in microbiology.

[47]  Marc Lipsitch,et al.  Mycobacterium tuberculosis mutation rate estimates from different lineages predict substantial differences in the emergence of drug resistant tuberculosis , 2013, Nature Genetics.

[48]  K. Yuen,et al.  Molecular Characterization of Isoniazid Resistance in Mycobacterium tuberculosis: Identification of a Novel Mutation in inhA , 2006, Antimicrobial Agents and Chemotherapy.

[49]  J. Farrar,et al.  Mutations Prevalent among Rifampin- and Isoniazid-Resistant Mycobacterium tuberculosis Isolates from a Hospital in Vietnam , 2006, Journal of Clinical Microbiology.

[50]  E. Rubin,et al.  Genes required for mycobacterial growth defined by high density mutagenesis , 2003, Molecular microbiology.

[51]  M. Chase,et al.  Use of whole genome sequencing to estimate the mutation rate of Mycobacterium tuberculosis during latent infection , 2011, Nature Genetics.

[52]  K. Feldmann,et al.  Geographic variation of the predictive values of genomic mutations associated with streptomycin resistance in Mycobacterium tuberculosis. , 1997, Molecular and cellular probes.

[53]  I. Bastian,et al.  Tuberculosis in Australia: bacteriologically confirmed cases and drug resistance, 2001. , 2003, Communicable diseases intelligence quarterly report.

[54]  Ying Zhang,et al.  Mutations in pncA, a gene encoding pyrazinamidase/nicotinamidase, cause resistance to the antituberculous drug pyrazinamide in tubercle bacillus , 1996, Nature Medicine.

[55]  Stefan Niemann,et al.  Variable host-pathogen compatibility in Mycobacterium tuberculosis. , 2006, Proceedings of the National Academy of Sciences of the United States of America.

[56]  R. Hasan,et al.  High Isoniazid Resistance Rates in Rifampicin Susceptible Mycobacterium tuberculosis Pulmonary Isolates from Pakistan , 2012, PloS one.

[57]  F. Balloux,et al.  Four decades of transmission of a multidrug-resistant Mycobacterium tuberculosis outbreak strain , 2015, Nature Communications.

[58]  Paul van Helden,et al.  Long-term outcomes of patients with extensively drug-resistant tuberculosis in South Africa: a cohort study , 2014, The Lancet.

[59]  J. V. van Horn,et al.  Penetration of isoniazid, rifampicin and pyrazinamide in tuberculous pleural effusion and psoas abscess. , 2004, The international journal of tuberculosis and lung disease : the official journal of the International Union against Tuberculosis and Lung Disease.

[60]  J. Musser,et al.  Mutations associated with pyrazinamide resistance in pncA of Mycobacterium tuberculosis complex organisms , 1997, Antimicrobial agents and chemotherapy.

[61]  P. Massoure,et al.  Significance of the Identification in the Horn of Africa of an Exceptionally Deep Branching Mycobacterium tuberculosis Clade , 2012, PloS one.

[62]  M. Reed,et al.  Major Mycobacterium tuberculosis Lineages Associate with Patient Country of Origin , 2009, Journal of Clinical Microbiology.

[63]  T. Clark,et al.  Recurrence due to Relapse or Reinfection With Mycobacterium tuberculosis: A Whole-Genome Sequencing Approach in a Large, Population-Based Cohort With a High HIV Infection Prevalence and Active Follow-up , 2014, The Journal of infectious diseases.

[64]  A. Khomenko,et al.  Standard short-course chemotherapy for drug-resistant tuberculosis: treatment outcomes in 6 countries. , 2000, JAMA.

[65]  Steven J. M. Jones,et al.  Whole-genome sequencing and social-network analysis of a tuberculosis outbreak. , 2011, The New England journal of medicine.

[66]  T. Sterling,et al.  A systematic review of gyrase mutations associated with fluoroquinolone-resistant Mycobacterium tuberculosis and a proposed gyrase numbering system. , 2012, The Journal of antimicrobial chemotherapy.

[67]  A. Telenti,et al.  Role of embB in natural and acquired resistance to ethambutol in mycobacteria , 1997, Antimicrobial agents and chemotherapy.

[68]  E. Böttger,et al.  Genetic alterations in streptomycin-resistant Mycobacterium tuberculosis: mapping of mutations conferring resistance , 1994, Antimicrobial Agents and Chemotherapy.

[69]  P. Klatser,et al.  Resistant mutants of Mycobacterium tuberculosis selected in vitro do not reflect the in vivo mechanism of isoniazid resistance , 2009, The Journal of antimicrobial chemotherapy.

[70]  H. Mills,et al.  Community-Wide Isoniazid Preventive Therapy Drives Drug-Resistant Tuberculosis: A Model-Based Analysis , 2013, Science Translational Medicine.

[71]  Thomas Abeel,et al.  Evolution of Extensively Drug-Resistant Tuberculosis over Four Decades: Whole Genome Sequencing and Dating Analysis of Mycobacterium tuberculosis Isolates from KwaZulu-Natal , 2015, PLoS medicine.

[72]  J. Childs,et al.  A household-based, case-control study of environmental factors associated with hantavirus pulmonary syndrome in the southwestern United States. , 1995, The American journal of tropical medicine and hygiene.

[73]  G. Bai,et al.  The rpsL gene and streptomycin resistance in single and multiple drug‐resistant strains of Mycobacterium tuberculosis , 1993, Molecular microbiology.

[74]  J C Sacchettini,et al.  Enzymatic characterization of the target for isoniazid in Mycobacterium tuberculosis. , 1995, Biochemistry.

[75]  T. Sterling,et al.  Prevalence, Risk Factors, and Treatment Outcomes of Isoniazid- and Rifampicin- Mono-Resistant Pulmonary Tuberculosis in Lima, Peru , 2016, PloS one.

[76]  Christina A. Cuomo,et al.  Pilon: An Integrated Tool for Comprehensive Microbial Variant Detection and Genome Assembly Improvement , 2014, PloS one.

[77]  J. Parkhill,et al.  Large-scale whole genome sequencing of M. tuberculosis provides insights into transmission in a high prevalence area , 2015, eLife.

[78]  Q. Zeng,et al.  Evolution of extensively drug-resistant tuberculosis over four decades revealed by whole genome sequencing of Mycobacterium tuberculosis from KwaZulu-Natal, South Africa , 2015 .

[79]  Daniel J. Wilson,et al.  Whole-genome sequencing to delineate Mycobacterium tuberculosis outbreaks: a retrospective observational study , 2013, The Lancet. Infectious diseases.

[80]  Richard Durbin,et al.  Sequence analysis Fast and accurate short read alignment with Burrows – Wheeler transform , 2009 .

[81]  T. Sterling,et al.  Fluoroquinolone resistance in Mycobacterium tuberculosis: the effect of duration and timing of fluoroquinolone exposure. , 2009, American journal of respiratory and critical care medicine.

[82]  Y. Hao,et al.  GenoType MTBDRplus Assay for Rapid Detection of Multidrug Resistance in Mycobacterium tuberculosis: A Meta-Analysis , 2016, PloS one.

[83]  Samuel A. Assefa,et al.  Elucidating Emergence and Transmission of Multidrug-Resistant Tuberculosis in Treatment Experienced Patients by Whole Genome Sequencing , 2013, PloS one.

[84]  H. Marttila,et al.  pncA Mutations in Pyrazinamide-ResistantMycobacterium tuberculosis Isolates from Northwestern Russia , 1999, Antimicrobial Agents and Chemotherapy.

[85]  M. Pai,et al.  Do We Need to Detect Isoniazid Resistance in Addition to Rifampicin Resistance in Diagnostic Tests for Tuberculosis? , 2014, PloS one.

[86]  E. Böttger,et al.  Molecular basis of streptomycin resistance in Mycobacterium tuberculosis: alterations of the ribosomal protein S12 gene and point mutations within a functional 16S ribosomal RNA pseudoknot , 1993, Molecular microbiology.

[87]  P. V. van Helden,et al.  Frequency and implications of pyrazinamide resistance in managing previously treated tuberculosis patients. , 2006, The international journal of tuberculosis and lung disease : the official journal of the International Union against Tuberculosis and Lung Disease.

[88]  F. Portaels,et al.  Relationship between Pyrazinamide Resistance, Loss of Pyrazinamidase Activity, and Mutations in the pncA Locus in Multidrug-Resistant Clinical Isolates of Mycobacterium tuberculosis , 1999, Antimicrobial Agents and Chemotherapy.

[89]  C. Brandon Ogbunugafor,et al.  Adaptive Landscape by Environment Interactions Dictate Evolutionary Dynamics in Models of Drug Resistance , 2016, PLoS Comput. Biol..

[90]  H. Jenkins,et al.  Quantifying the Burden and Trends of Isoniazid Resistant Tuberculosis, 1994–2009 , 2011, PloS one.

[91]  R. Jou,et al.  Performance Assessment of the GenoType MTBDRplus Test and DNA Sequencing in Detection of Multidrug-Resistant Mycobacterium tuberculosis , 2009, Journal of Clinical Microbiology.

[92]  S. Niemann,et al.  Significance of Mutations in embB Codon 306 for Prediction of Ethambutol Resistance in Clinical Mycobacterium tuberculosis Isolates , 2006, Antimicrobial Agents and Chemotherapy.

[93]  G. Drusano,et al.  Concentration-Dependent Mycobacterium tuberculosis Killing and Prevention of Resistance by Rifampin , 2007, Antimicrobial Agents and Chemotherapy.

[94]  Andrew J. Oler,et al.  Whole-Genome Sequencing of Mycobacterium tuberculosis Provides Insight into the Evolution and Genetic Composition of Drug-Resistant Tuberculosis in Belarus , 2016, Journal of Clinical Microbiology.

[95]  D. Mitchison Role of individual drugs in the chemotherapy of tuberculosis. , 2000, The international journal of tuberculosis and lung disease : the official journal of the International Union against Tuberculosis and Lung Disease.

[96]  Alex Salazar,et al.  Normalizing alternate representations of large sequence variants across multiple bacterial genomes , 2015, BMC Bioinformatics.

[97]  A. Telenti,et al.  Detection of rifampicin-resistance mutations in Mycobacterium tuberculosis , 1993, The Lancet.

[98]  Phelim Bradley,et al.  Whole-genome sequencing for prediction of Mycobacterium tuberculosis drug susceptibility and resistance: a retrospective cohort study , 2015, The Lancet. Infectious diseases.

[99]  S. Cole,et al.  Effect of katG Mutations on the Virulence of Mycobacterium tuberculosis and the Implication for Transmission in Humans , 2002, Infection and Immunity.

[100]  D. van Soolingen,et al.  Pre-Existing Isoniazid Resistance, but Not the Genotype of Mycobacterium Tuberculosis Drives Rifampicin Resistance Codon Preference in Vitro , 2012, PloS one.

[101]  T. Hinkley,et al.  Fitness Costs of Drug Resistance Mutations in Multidrug-Resistant Mycobacterium tuberculosis: A Household-Based Case-Control Study. , 2016, The Journal of infectious diseases.

[102]  K. Kam,et al.  Genetic and phenotypic characterization of drug-resistant Mycobacterium tuberculosis isolates in Hong Kong , 2007, The Journal of antimicrobial chemotherapy.

[103]  A. Benedetti,et al.  Standardized Treatment of Active Tuberculosis in Patients with Previous Treatment and/or with Mono-resistance to Isoniazid: A Systematic Review and Meta-analysis , 2009, PLoS medicine.

[104]  T. Clark,et al.  Unraveling Mycobacterium tuberculosis genomic diversity and evolution in Lisbon, Portugal, a highly drug resistant setting , 2014, BMC Genomics.

[105]  Dan S. Tawfik,et al.  Initial Mutations Direct Alternative Pathways of Protein Evolution , 2011, PLoS genetics.

[106]  K. Jung,et al.  Characterization of pncA mutations of pyrazinamide-resistant Mycobacterium tuberculosis in Korea. , 2001, Journal of Korean medical science.

[107]  P. Beckert,et al.  Detection of drug-resistant tuberculosis by Xpert MTB/RIF in Swaziland. , 2015, The New England journal of medicine.

[108]  Eduardo Gotuzzo,et al.  Rapid molecular detection of tuberculosis and rifampin resistance. , 2010, The New England journal of medicine.

[109]  J. Pasipanodya,et al.  A new evolutionary and pharmacokinetic-pharmacodynamic scenario for rapid emergence of resistance to single and multiple anti-tuberculosis drugs. , 2011, Current opinion in pharmacology.

[110]  M. Makino,et al.  Detection of kanamycin-resistant Mycobacterium tuberculosis by identifying mutations in the 16S rRNA gene. , 1998, Journal of clinical microbiology.

[111]  Dongfang Li,et al.  Genome sequencing of 161 Mycobacterium tuberculosis isolates from China identifies genes and intergenic regions associated with drug resistance , 2013, Nature Genetics.

[112]  Robert C. Wolpert,et al.  A Review of the , 1985 .

[113]  George M Church,et al.  Tuberculosis Drug Resistance Mutation Database , 2009, PLoS medicine.

[114]  D. Snider,et al.  U.S. Public Health Service Cooperative trial of three rifampin-isoniazid regimens in treatment of pulmonary tuberculosis. , 2015, The American review of respiratory disease.

[115]  Stefan Niemann,et al.  Whole Genome Sequencing versus Traditional Genotyping for Investigation of a Mycobacterium tuberculosis Outbreak: A Longitudinal Molecular Epidemiological Study , 2013, PLoS medicine.

[116]  S. Gillespie,et al.  The effect of oxidative stress on the mutation rate of Mycobacterium tuberculosis with impaired catalase/peroxidase function. , 2008, The Journal of antimicrobial chemotherapy.

[117]  Y. Kazumi,et al.  Mutation in pncA is a major mechanism of pyrazinamide resistance in Mycobacterium tuberculosis. , 1997, Tubercle and lung disease : the official journal of the International Union against Tuberculosis and Lung Disease.

[118]  K. Holt,et al.  Out-of-Africa migration and Neolithic co-expansion of Mycobacterium tuberculosis with modern humans , 2013, Nature Genetics.

[119]  N. Awofeso Anti-tuberculosis medication side-effects constitute major factor for poor adherence to tuberculosis treatment. , 2008, Bulletin of the World Health Organization.

[120]  P. Schultz,et al.  Mechanistic Studies of the Oxidation of Isoniazid by the Catalase Peroxidase from Mycobacterium tuberculosis , 1994 .

[121]  H. Soini,et al.  A Ser315Thr Substitution in KatG Is Predominant in Genetically Heterogeneous Multidrug-Resistant Mycobacterium tuberculosis Isolates Originating from the St. Petersburg Area in Russia , 1998, Antimicrobial Agents and Chemotherapy.

[122]  A. Rahmo,et al.  Genotypic detection of rifampicin-resistant M. tuberculosis strains in Syrian and Lebanese patients. , 2012, Journal of infection and public health.

[123]  K. Wan,et al.  Prevalence of mutations conferring resistance among multi- and extensively drug-resistant Mycobacterium tuberculosis isolates in China , 2015, The Journal of Antibiotics.

[124]  E. Mohammadi,et al.  Barriers and facilitators related to the implementation of a physiological track and trigger system: A systematic review of the qualitative evidence , 2017, International journal for quality in health care : journal of the International Society for Quality in Health Care.